The PRO-SCALP study offers critical insights into the real-world application of CAL/BDP PAD-cream for adults suffering from scalp psoriasis. Managing this condition is often difficult because traditional topical treatments can be greasy or unpleasant to use. This prospective, multicentre study evaluated the effectiveness and patient satisfaction of a novel cream formulation. Researchers conducted the study across Germany, Spain, and the United Kingdom, focusing on how this treatment performs in routine clinical practice rather than controlled trials.

Clinical Success with CAL/BDP PAD-Cream

Clinicians participating in the study reported highly positive results after eight weeks of treatment. Specifically, 77.6% of patients achieved a scalp-PGA score of 0 or 1, indicating that their skin was clear or almost clear. Moreover, 68.4% of the participants met the strict criteria for treatment success. This success was defined as achieving a clear status alongside at least a 2-point improvement from the baseline. Furthermore, significant improvements occurred in the S-mPASI scores, demonstrating that CAL/BDP PAD-cream effectively reduces the physical severity of the disease.

Patient-reported outcomes were equally impressive throughout the study period. In addition to clinical clearing, patients experienced a significant reduction in itching and sleep disturbances. The global satisfaction score reached 76.0 on the TSQM-9 scale, reflecting the high value patients placed on the treatment's effectiveness and convenience. Additionally, nearly 60% of patients maintained high adherence to the daily regimen. Consequently, the combination of clinical efficacy and ease of use addresses the long-standing challenges of patient compliance in scalp psoriasis management.

The Role of PAD Technology in Patient Adherence

The success of this treatment stems largely from the Polyaphron Dispersion (PAD) technology used in its formulation. This technology allows for an aqueous, non-greasy cream that absorbs quickly into the skin. Patients often prefer this texture over traditional ointments or gels, which can leave a messy residue in the hair. Because the cream feels better on the skin, patients are more likely to apply it consistently. Overall, the PRO-SCALP study confirms that CAL/BDP PAD-cream provides a potent and patient-friendly solution for managing mild-to-moderate scalp psoriasis.

Frequently Asked Questions

How does CAL/BDP PAD-cream differ from other psoriasis treatments?

Unlike many greasy ointments, this treatment uses PAD technology to create a stable, water-based cream. This formulation enhances skin penetration while remaining cosmetically acceptable for hair-bearing areas.

What were the primary results of the PRO-SCALP study?

The study showed that over 77% of patients achieved clear or almost clear scalp skin within eight weeks. It also highlighted significant improvements in itching, sleep, and overall quality of life.

Is adherence higher with this specific cream?

Yes, the study reported that about 60% of patients showed high adherence. The non-greasy texture and ease of application likely contribute to why patients use it more consistently than other topical options.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional services. Always seek the advice of your physician or other qualified health provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

López Estebaranz JL et al. Patient and clinician reported outcomes of calcipotriol/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, non-interventional, multicentre PRO-SCALP study. Clin Exp Dermatol. 2026 Apr 29. doi: undefined. PMID: 42052895.

Stein Gold L, et al. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420-425.

Pinter A, et al. Impact of calcipotriene and betamethasone dipropionate cream with PAD technology on scalp-PGA success: An interim analysis of the PRO-SCALP study. EADV Congress 2024.